BRPI0707560B8 - combinação de análogos de somatostatina com seletividade diferente para subtipos de receptores de somatostatina humana, seu uso, composição farmacêutica, e embalagem comercial - Google Patents
combinação de análogos de somatostatina com seletividade diferente para subtipos de receptores de somatostatina humana, seu uso, composição farmacêutica, e embalagem comercialInfo
- Publication number
- BRPI0707560B8 BRPI0707560B8 BRPI0707560A BRPI0707560A BRPI0707560B8 BR PI0707560 B8 BRPI0707560 B8 BR PI0707560B8 BR PI0707560 A BRPI0707560 A BR PI0707560A BR PI0707560 A BRPI0707560 A BR PI0707560A BR PI0707560 B8 BRPI0707560 B8 BR PI0707560B8
- Authority
- BR
- Brazil
- Prior art keywords
- somatostatin
- combination
- receptor subtypes
- pharmaceutical composition
- different selectivity
- Prior art date
Links
- 101000632994 Homo sapiens Somatostatin Proteins 0.000 title abstract 2
- 102000045305 human SST Human genes 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 102000005962 receptors Human genes 0.000 title abstract 2
- 108020003175 receptors Proteins 0.000 title abstract 2
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical class C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 title abstract 2
- 238000004806 packaging method and process Methods 0.000 title 1
- 229940075620 somatostatin analogue Drugs 0.000 title 1
- 101000633010 Rattus norvegicus Somatostatin Proteins 0.000 abstract 1
- 102000005157 Somatostatin Human genes 0.000 abstract 1
- 108010056088 Somatostatin Proteins 0.000 abstract 1
- 108050001286 Somatostatin Receptor Proteins 0.000 abstract 1
- 102000011096 Somatostatin receptor Human genes 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000000816 peptidomimetic Substances 0.000 abstract 1
- 229960000553 somatostatin Drugs 0.000 abstract 1
- NHXLMOGPVYXJNR-UHFFFAOYSA-N srif Chemical compound N1C(=O)C(C(C)O)NC(=O)C(CCCCN)NC(=O)C(CC=2C3=CC=CC=C3NC=2)NC(=O)C(CC=2C=CC=CC=2)NC(=O)C(CC=2C=CC=CC=2)NC(=O)C(CC(N)=O)NC(=O)C(CCCCN)NC(=O)C(NC(=O)CNC(=O)C(C)N)CSSCC(C(O)=O)NC(=O)C(CO)NC(=O)C(C(O)C)NC(=O)C1CC1=CC=CC=C1 NHXLMOGPVYXJNR-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/31—Somatostatins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/655—Somatostatins
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Oncology (AREA)
Abstract
combinação de análogos de somatostatina com seletividade diferente para subtipos de receptores de somatostatina humana. a presente invenção refere-se a uma combinação de dois ou mais peptidomiméticos de somatostatina (srif) (também chamados de análogos de somatostatina ou srif) que possuem seletividade diferente para os cinco subtipos de receptores de somatostatina humanos, ao uso de tal combinação no tratamento de uma doença mediada pela ativação de receptores de somatostatina, e a composições farmacêuticas compreendendo tal combinação.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0602639.7A GB0602639D0 (en) | 2006-02-09 | 2006-02-09 | Organic compounds |
| GB0602639.7 | 2006-02-09 | ||
| GB06026397 | 2006-02-09 | ||
| PCT/EP2007/001036 WO2007096055A1 (en) | 2006-02-09 | 2007-02-07 | Combination of somatostatin-analogs with different selectivity for human somatostatin receptor subtypes |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BRPI0707560A2 BRPI0707560A2 (pt) | 2011-05-10 |
| BRPI0707560B1 BRPI0707560B1 (pt) | 2019-06-04 |
| BRPI0707560B8 true BRPI0707560B8 (pt) | 2021-05-25 |
Family
ID=36119810
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0707560A BRPI0707560B8 (pt) | 2006-02-09 | 2007-02-07 | combinação de análogos de somatostatina com seletividade diferente para subtipos de receptores de somatostatina humana, seu uso, composição farmacêutica, e embalagem comercial |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US8450272B2 (pt) |
| EP (1) | EP1988914B1 (pt) |
| JP (1) | JP5189993B2 (pt) |
| KR (1) | KR101466410B1 (pt) |
| CN (1) | CN101378775B (pt) |
| AT (1) | ATE519498T1 (pt) |
| AU (1) | AU2007218297B2 (pt) |
| BR (1) | BRPI0707560B8 (pt) |
| CA (1) | CA2638065C (pt) |
| ES (1) | ES2369155T3 (pt) |
| GB (1) | GB0602639D0 (pt) |
| PL (1) | PL1988914T3 (pt) |
| PT (1) | PT1988914E (pt) |
| RU (1) | RU2451520C2 (pt) |
| WO (1) | WO2007096055A1 (pt) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006077362A1 (en) | 2005-01-21 | 2006-07-27 | Camurus Ab | Pharmaceutical lipid compositions |
| GB0602639D0 (en) * | 2006-02-09 | 2006-03-22 | Novartis Ag | Organic compounds |
| ES2399651T3 (es) * | 2008-07-08 | 2013-04-02 | Novartis Ag | Utilización de pasireotida para el tratamiento de la hipoglucemia hiperinsulenémica endógena |
| AU2013265210B2 (en) * | 2012-05-25 | 2016-09-15 | Camurus Ab | Somatostatin receptor agonist formulations |
| TWI633887B (zh) | 2012-05-31 | 2018-09-01 | 大塚製藥股份有限公司 | 用於預防及／或治療多囊性腎臟病之藥物 |
| WO2014165607A2 (en) * | 2013-04-02 | 2014-10-09 | Stealth Peptides International, Inc. | Aromatic-cationic peptide formulations, compositions and methods of use |
| EP3007704B1 (en) * | 2013-06-13 | 2021-01-06 | Antisense Therapeutics Ltd | Combination therapy for acromegaly |
| CN120131956A (zh) * | 2023-12-11 | 2025-06-13 | 中山大学中山眼科中心 | 生长激素抑制剂的用途、和含有生长激素抑制剂的药物组合物、制剂、及其装置 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2774591B1 (fr) * | 1998-02-12 | 2000-05-05 | Lipha | Composition pharmaceutique comprenant l'association metformine et fibrate et son utilisation pour la preparation de medicaments destines a reduire l'hyperglycemie |
| GB0018891D0 (en) * | 2000-08-01 | 2000-09-20 | Novartis Ag | Organic compounds |
| DE60232203D1 (de) * | 2001-03-06 | 2009-06-10 | Il Consorzio Ferrara Richerche | Verfahren zur Modulation der Proliferation von Schilddrüsenkrebszellen |
| PL374174A1 (en) * | 2001-06-25 | 2005-10-03 | Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. | Pharmaceutical compositions which inhibit proliferation of pituitary adenomas and method of use thereof |
| US7094753B2 (en) * | 2001-11-21 | 2006-08-22 | Societe De Conseils De Recherches Et D'applications Scientifiques, Sas | Somatostatin analog and uses thereof |
| WO2005041901A2 (en) | 2003-11-03 | 2005-05-12 | Elixir Pharmaceuticals, Inc. | Therapeutics using somatostatin agonists |
| EP1689844A1 (en) * | 2003-12-03 | 2006-08-16 | The Procter & Gamble Company | Method, articles and compositions for cleaning bathroom surfaces |
| ES2383303T3 (es) * | 2005-11-10 | 2012-06-20 | Chemi S.P.A. | Formulaciones de inhibidores de la liberación prolongada de la hormona del crecimiento análogos de la somatostatina |
| GB0602639D0 (en) * | 2006-02-09 | 2006-03-22 | Novartis Ag | Organic compounds |
-
2006
- 2006-02-09 GB GBGB0602639.7A patent/GB0602639D0/en not_active Ceased
-
2007
- 2007-02-07 WO PCT/EP2007/001036 patent/WO2007096055A1/en not_active Ceased
- 2007-02-07 EP EP07703319A patent/EP1988914B1/en active Active
- 2007-02-07 AU AU2007218297A patent/AU2007218297B2/en active Active
- 2007-02-07 CN CN2007800049919A patent/CN101378775B/zh active Active
- 2007-02-07 PL PL07703319T patent/PL1988914T3/pl unknown
- 2007-02-07 CA CA2638065A patent/CA2638065C/en active Active
- 2007-02-07 ES ES07703319T patent/ES2369155T3/es active Active
- 2007-02-07 US US12/162,715 patent/US8450272B2/en active Active
- 2007-02-07 PT PT07703319T patent/PT1988914E/pt unknown
- 2007-02-07 KR KR1020087019493A patent/KR101466410B1/ko active Active
- 2007-02-07 RU RU2008136073/15A patent/RU2451520C2/ru active
- 2007-02-07 BR BRPI0707560A patent/BRPI0707560B8/pt active IP Right Grant
- 2007-02-07 AT AT07703319T patent/ATE519498T1/de active
- 2007-02-07 JP JP2008553675A patent/JP5189993B2/ja active Active
-
2013
- 2013-04-30 US US13/873,289 patent/US9149510B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2007218297B2 (en) | 2010-09-09 |
| BRPI0707560A2 (pt) | 2011-05-10 |
| BRPI0707560B1 (pt) | 2019-06-04 |
| CN101378775B (zh) | 2013-06-12 |
| JP2009526002A (ja) | 2009-07-16 |
| AU2007218297A1 (en) | 2007-08-30 |
| ATE519498T1 (de) | 2011-08-15 |
| US20090029910A1 (en) | 2009-01-29 |
| RU2008136073A (ru) | 2010-03-20 |
| KR101466410B1 (ko) | 2014-11-27 |
| WO2007096055A1 (en) | 2007-08-30 |
| PL1988914T3 (pl) | 2012-01-31 |
| CA2638065A1 (en) | 2007-08-30 |
| RU2451520C2 (ru) | 2012-05-27 |
| US9149510B2 (en) | 2015-10-06 |
| CN101378775A (zh) | 2009-03-04 |
| EP1988914A1 (en) | 2008-11-12 |
| KR20080106896A (ko) | 2008-12-09 |
| EP1988914B1 (en) | 2011-08-10 |
| CA2638065C (en) | 2016-03-29 |
| US8450272B2 (en) | 2013-05-28 |
| US20130237480A1 (en) | 2013-09-12 |
| JP5189993B2 (ja) | 2013-04-24 |
| PT1988914E (pt) | 2011-10-18 |
| GB0602639D0 (en) | 2006-03-22 |
| ES2369155T3 (es) | 2011-11-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2011002467A1 (es) | Compuestos derivados de 6-(3-aza-biciclo[3.1.0]hex-3-il)-2-fenilpirimidinas, antagonistas del receptor p2y 12; composicion farmaceutica que los comprende; y su uso en el tratamiento de trastornos oclusivos. pct fase nacional. | |
| WO2008021851A3 (en) | Novel compounds as antagonists or inverse agonists for opioid receptors | |
| GT200800250A (es) | Arilimidazolonas y ariltriazolonas sustituidas como inhibidores de receptores de vasopresina | |
| CO6361994A2 (es) | Antagonistas del receptor de orexina de isonicotinamida | |
| GT200600453A (es) | Indoles de acilo, composiciones que contienen dichos compuestos y procedimientos de uso | |
| EA200970132A1 (ru) | Аналоги морфолинила и пирролидинила | |
| MY163055A (en) | Polycyclic antagonists of lysophosphatidic acid receptors | |
| WO2010077883A3 (en) | Antagonists of lysophosphatidic acid receptors | |
| EA201270467A1 (ru) | Полициклические соединения в качестве антагонистов рецепторов лизофосфатидной кислоты | |
| UY28766A1 (es) | Compuestos heteropolicíclicos adicionales y su uso como antagonistas del receptor de glutamato metabotrópico | |
| UY32225A (es) | Antagonistas de cicloalcano[b]azaindol de los receptores de la prostaglandina d2 | |
| ATE469895T1 (de) | Cgrp-rezeptorantagonisten | |
| BRPI0710232B8 (pt) | composto antagonista do receptor de il-8, composição farmacêutica que compreende o dito composto e uso do mesmo para o tratamento de uma doença mediada por quimiocina | |
| DE602007012072D1 (de) | Orantagonisten | |
| GT200900057A (es) | 4-[4-({[4-cloro-3-(trifluorometil)fenil]carbamoil}amino)-3-fluorofenoxi]-n-metilpiridina-2-carboxamida monohidrato | |
| EA201170302A1 (ru) | Процессированные аналоги глюкозозависимого инсулинотропного полипетида | |
| CR10497A (es) | Derivados de piperazinilo utiles en el tratamiento de enfermedades mediadas por el receptor gpr38 | |
| MA32622B1 (fr) | Derives de carbonate de quinuclidine et composition medicinale les comprenant | |
| PT1988914E (pt) | Combinação de análogos de somatostatina com diferente selectividade para subtipos do receptor da somatostatina humana | |
| UY31622A1 (es) | Antagonistas de aminoalquilbifenilo n,n-disubstituidos de receptores de prostaglandina d2 | |
| CY1118044T1 (el) | Παρασκευασμα συνδυασμου με ανταγωνιστη και κορτικοστεροειδες | |
| GT200800187A (es) | Compuestos de tetrahidropiridotienopirimidina y procedimientos de uso de los mismos | |
| CO6280470A2 (es) | Bis-piridilpiridonas como antaginistas del receptor 1 de la hormona concentradora de la melanina | |
| CL2008003266A1 (es) | Compuestos derivados de pirimidindiona y triazindiona sustituidas con cicloguanidina, utiles como antagonista del receptor de procineticina; composicion farmaceutica que comprende dichos compuestos; y uso en el tratamiento de enfermedades gastrointestinales. | |
| CY1113726T1 (el) | Χρηση της πασιρεοτιδης για την αντιμετωπιση της ενδογενους υπερινσουλιναιμικης υπογλυκαιμιας |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 04/06/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 04/06/2019, OBSERVADAS AS CONDICOES LEGAIS |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 07/02/2007 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |